Adaptimmune Therapeutics (ADAP) Competitors $0.06 +0.01 (+10.89%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.06 +0.00 (+8.75%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADAP vs. CALC, ACRV, EGRX, OTLK, LVTX, GBIO, TELO, XFOR, PLUR, and ESLAShould you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include CalciMedica (CALC), Acrivon Therapeutics (ACRV), Eagle Pharmaceuticals (EGRX), Oncobiologics (OTLK), LAVA Therapeutics (LVTX), Generation Bio (GBIO), Telomir Pharmaceuticals (TELO), X4 Pharmaceuticals (XFOR), Pluri (PLUR), and Estrella Immunopharma (ESLA). These companies are all part of the "pharmaceutical products" industry. Adaptimmune Therapeutics vs. Its Competitors CalciMedica Acrivon Therapeutics Eagle Pharmaceuticals Oncobiologics LAVA Therapeutics Generation Bio Telomir Pharmaceuticals X4 Pharmaceuticals Pluri Estrella Immunopharma CalciMedica (NASDAQ:CALC) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk. Does the media refer more to CALC or ADAP? In the previous week, Adaptimmune Therapeutics had 1 more articles in the media than CalciMedica. MarketBeat recorded 4 mentions for Adaptimmune Therapeutics and 3 mentions for CalciMedica. CalciMedica's average media sentiment score of 0.63 beat Adaptimmune Therapeutics' score of 0.47 indicating that CalciMedica is being referred to more favorably in the media. Company Overall Sentiment CalciMedica Positive Adaptimmune Therapeutics Neutral Is CALC or ADAP more profitable? CalciMedica has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -260.82%. Adaptimmune Therapeutics' return on equity of -163.73% beat CalciMedica's return on equity.Company Net Margins Return on Equity Return on Assets CalciMedicaN/A -206.51% -103.81% Adaptimmune Therapeutics -260.82%-163.73%-75.83% Which has better valuation and earnings, CALC or ADAP? CalciMedica has higher earnings, but lower revenue than Adaptimmune Therapeutics. CalciMedica is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalciMedicaN/AN/A-$13.70M-$1.60-1.98Adaptimmune Therapeutics$178.03M0.08-$70.81M-$0.65-0.09 Do analysts rate CALC or ADAP? CalciMedica presently has a consensus price target of $16.00, indicating a potential upside of 404.73%. Adaptimmune Therapeutics has a consensus price target of $1.35, indicating a potential upside of 2,313.69%. Given Adaptimmune Therapeutics' higher probable upside, analysts clearly believe Adaptimmune Therapeutics is more favorable than CalciMedica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CalciMedica 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Adaptimmune Therapeutics 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk and volatility, CALC or ADAP? CalciMedica has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.24, indicating that its share price is 124% more volatile than the S&P 500. Do institutionals and insiders have more ownership in CALC or ADAP? 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. 41.5% of CalciMedica shares are held by company insiders. Comparatively, 12.7% of Adaptimmune Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryAdaptimmune Therapeutics beats CalciMedica on 9 of the 14 factors compared between the two stocks. Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAP vs. The Competition Export to ExcelMetricAdaptimmune TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.39M$3.20B$5.87B$10.13BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-0.0921.1774.5225.93Price / Sales0.08436.80537.17192.28Price / CashN/A46.6837.5660.44Price / Book1.129.6112.166.29Net Income-$70.81M-$53.29M$3.28B$270.77M7 Day PerformanceN/A0.28%0.87%3.88%1 Month PerformanceN/A5.73%4.96%4.88%1 Year PerformanceN/A10.52%60.74%26.01% Adaptimmune Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAPAdaptimmune Therapeutics2.1174 of 5 stars$0.06+10.9%$1.35+2,313.7%-94.9%$13.39M$178.03M-0.09490Short Interest ↑Gap UpCALCCalciMedica2.4705 of 5 stars$3.09+0.3%$16.00+417.8%-23.8%$43.03MN/A-1.9330Short Interest ↑ACRVAcrivon Therapeutics3.5812 of 5 stars$1.79+34.6%$15.50+765.9%-83.5%$41.84MN/A-0.8058Short Interest ↓Gap UpHigh Trading VolumeEGRXEagle PharmaceuticalsN/A$3.21+5.9%N/A-16.2%$41.69M$257.55M0.00100Gap DownOTLKOncobiologics2.133 of 5 stars$0.95+1.1%$9.60+915.1%-84.0%$41.53MN/A-1.6620Short Interest ↑LVTXLAVA Therapeutics1.6509 of 5 stars$1.55-1.3%$2.69+73.2%-8.3%$41.30M$11.98M-1.4860Short Interest ↑GBIOGeneration Bio4.0432 of 5 stars$5.83-2.7%$10.67+83.0%-76.6%$40.35M$19.89M-0.54150Positive NewsShort Interest ↓TELOTelomir Pharmaceuticals2.0043 of 5 stars$1.23-0.8%$15.00+1,119.5%-77.1%$40.03MN/A-2.281Short Interest ↑XFORX4 Pharmaceuticals4.6387 of 5 stars$3.39-3.1%$34.17+907.9%-84.0%$39.93M$2.56M-0.2380Positive NewsShort Interest ↓PLURPluri2.6774 of 5 stars$4.73-5.8%$12.00+153.7%-1.8%$39.51M$330K-0.86150News CoverageUpcoming EarningsGap DownESLAEstrella Immunopharma2.484 of 5 stars$1.00-4.8%$16.00+1,500.0%-10.2%$38.92MN/A-3.85N/AGap UpHigh Trading Volume Related Companies and Tools Related Companies CALC Alternatives ACRV Alternatives EGRX Alternatives OTLK Alternatives LVTX Alternatives GBIO Alternatives TELO Alternatives XFOR Alternatives PLUR Alternatives ESLA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADAP) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADAP Stock Alerts